Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "markets"

943 News Found

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
News | February 27, 2025

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies


Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences
People | February 23, 2025

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025


Roche Diagnostics India screens 5,000 children for eye health
Healthcare | February 21, 2025

Roche Diagnostics India screens 5,000 children for eye health

Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children


Orchid Pharma's Alathur API facility successfully completes USFDA inspection
Drug Approval | February 20, 2025

Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics


Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
News | February 17, 2025

Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY


Zydus Lifesciences posts Q3 FY25 net profit higher at Rs 1,024 Cr
News | February 10, 2025

Zydus Lifesciences posts Q3 FY25 net profit higher at Rs 1,024 Cr

During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent


Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
News | February 08, 2025

Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr

During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.


Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
News | February 07, 2025

Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr

Branded formulation business continues to perform well across domestic and export markets